Indication
Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
Medicine details
- Medicine name:
- seladelpar (Livdelzi)
- SMC ID:
- SMC2899
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Resubmission
- Publication due date:
- 09 March 2026
- SMC meeting date:
- 03 February 2026
- Patient group submission deadline:
- TBC